Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI(R)” for the Treatment of Early Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass., Nov. 28, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for “LEQEMBI(R)” (brand name, generic name: lecanemab) seeking approval […]


















